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Abstract
Rationale: An isolated splenic metastasis is a rare phenomenon noted in advanced stage melanoma. We report the role of
radiofrequency (RF) -based splenic-preserving splenectomy in a patient with a solitary splenic metastasis from advanced stage
melanoma that was managed with checkpoint inhibitors.
Patient concerns:We report a case of a 60-year-old man who presented with multiple lung metastases and a solitary splenic
metastasis with advanced stage melanoma following excision of primary from his trunk 2.3 years back.
Diagnosis: Considering the diagnosis of advanced stage melanoma with multiple lung metastases and a solitary splenic
metastasis, and its ongoing progressive nature. This case was discussed in the tumour board meeting.
Interventions:A decision was made to commence treatment with immunotherapy in the form of PD-1 inhibitor (programmed cell
death 1 receptor) pembrolizumab. Follow-up restaging computer tomography (CT) scan of the abdomen and chest showed a
signiﬁcant reduction in the lung and chest wall lesions, but the splenic lesion remained unchanged. Given the lack of response to
treatment in the splenic metastasis and the signiﬁcant decrease in lung metastases, the multidisciplinary team decided that a partial
splenectomy combined with continued immunotherapy treatment would be appropriate as the success of immunotherapy was
imminent within the splenic preservation.
Outcomes: The postoperative recovery was smooth and the patient was discharged from hospital on the sixth postoperative day
with normal platelets and white blood cells. The histopathological analysis of the resected specimen showed a metastatic melanoma
with negative margins.
At 10-month follow-up after the splenic resection the patient had not experienced further tumour recurrences.
Lessons: Spleen-preserving resection for an isolated, solitary splenic metastasis of melanoma is a feasible approach as it not only
preserves the ongoing efﬁcacy of checkpoint inhibitors by preserving the physiological T cell milieu, but the immunomodulation
properties of RF can produce potentially additional therapeutic beneﬁt.
Abbreviations: anti-CTLA4= anticytotoxic T-lymphocyte-associated protein 4, anti-PD-1= antiprogrammed cell death protein 1,
anti-PD-L1 = antiprogrammed cell death-ligand 1, BRAF = B-Raf protein kinase, CT = computer tomography, MEK = mitogen-
activated extracellular signal regulated kinase, PD-1 = programmed cell death 1 receptor, RF = radiofrequency.
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11. Introduction
The management of metastatic melanoma has improved
considerably in recent years with the introduction of immune
checkpoint blockade drugs (anti-CTLA4: anticytotoxic T-
lymphocyte-associated protein 4; anti-PD-1: antiprogrammed
cell death protein 1; and anti-PD-L1: antiprogrammed cell death-
ligand 1) and targeted therapy, such as BRAF (B-Raf protein
kinase) and MEK (mitogen-activated extracellular signal regu-
lated kinase) inhibitors.[1,2]
The programmed cell death 1 receptor (PD-1), an inhibitory
receptor present on the activated T cells, binds to its ligand (PD-
L1) present on the tumor cells and downregulates the activated T
cell to produce an effective immune response.[3] Thus antibodies
directed against PD-1 (nivolumab, pembrolizumab) or the PD-L1
ligand may restore or augment the antitumor immune response
making it able to suppress the cancerous melanoma cells.[4–6]
Metastasis to the spleen is considered as a rare event and marks
the terminal end of the spectrum of melanoma disease processes.
Recently, the reported incidence of splenic metastasis has increased
owing to the improvement in medical imaging and the long-term
follow-up of patients with melanoma.[7–10] There are no speciﬁc
Figure 1. Axial CT scan shows a hypodense lesion in the spleen.
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melanomapatients.Nevertheless,many case reports in the literature
suggest improved survival following surgical resection. The surgical
procedure in the form of open or laparoscopic splenectomy seems a
realistic and reasonable therapeutic option.[11,12]
However, considering the success of checkpoint inhibitors and
the availability of a radiofrequency (RF) device to assist with the
surgery allows partial splenectomy to be offered as a therapeutic
option. The rationale behind RF-based splenectomy is self-
explanatory in terms of maintenance of immunological beneﬁts
of immunotherapy through the preservation of spleen. Together
with that, post RF ablative changes in the immune system have
been considered as evidence for both a systemic and local
immunomodulatory effect.[13–15] Furthermore, the immunomod-
ulatory effects of RF could be potentially beneﬁcial in the
augmentation of therapeutic effects of checkpoint inhibi-
tors.[16,17] Immunologically, splenectomy is associated with loss
of memory B cells which are preserved in the case of a partial
splenectomy, where the number of T and B lymphocytes increase
as do the number of monocytes in the red pulp.[18–20]
Here, we report the role of RF-based splenic-preserving
splenectomy in a patient with a solitary splenic metastasis in
advanced stage melanoma that was managed with checkpoint
inhibitors.Figure 2. Intraoperative sonogram shows hypoechoic lesion in the spleen.2. Case report
2.1. Case presentation
A 60-year-old male patient presented to our institute for the
management of a solitary splenic metastasis. The patient was
diagnosed with melanoma following excision of a nevus from his
trunk and sentinel lymph node biopsy in November 2014. The
primary histopathological assessment revealed a Breslow thick-
ness of 1.8mm, Stage T2 lesion with tumor-free margin and no
lymph node metastasis. The patient was doing well until May
2015 when a follow-up CT scan revealed 2 indeterminate
subcentimetric lung lesions in the lower left lobe.
He remained asymptomatic until October 2015 when he
developed a suspicious lesion on his trunk. Following a wide local
excision and histopathological assessment the lesion was
reported as a T1 lesion of a Breslow thickness of 0.6mm with
tumor-free margins.
The repeat follow-up CT scan in November 2015 showed
development of an enlarged suspicious right axillary lymph node.
An ultrasound-guided biopsy conﬁrmed this as ametastatic lymph
node secondary to melanoma. In the presence of this diagnosis a
right axillary lymphadenectomy was completed.
The patient remained asymptomatic until February 2016 when
he developed sepsis and cellulitis at the site of lymphadenectomy.
He was managed successfully with incision and drainage and
administration of parenteral antibiotics. At the next follow-up CT
scan3new lung lesions in the chestwallwere reported, althoughno
change was noted in earlier lesions seen in the right lung.
In presence of progressive disease, the decision was made to
start immunotherapy a PD-1 inhibitor, pembrolizumab (10mg/
kg/every 3 weeks intravenously), in June 2016. The subsequent
follow-up scan in August 2016 showed a new solitary metastatic
lesion in the spleen. He was maintained on the pembrolizumab,
and follow-up restaging CT scan performed in November 2016
revealed a signiﬁcant reduction in the lung and chest wall lesions,
but the splenic lesion remained unchanged (Fig. 1). The
pembrolizumab treatment was well tolerated, and the perfor-2mance status of patient improved; however, he developed an
adverse effect of treatment as extensive changes in the lung
compatible with ﬁbrosis was revealed on imaging. This was
suggestive of a diagnosis of immune-related pneumonitis, which
improved with stopping the pembrolizumab and giving oral
prednisolone. The pembrolizumab was reintroduced following
resolution of pneumonitis.
In view of the nonresponse to treatment of the splenic
metastasis, the multidisciplinary team evaluated the available
options and decided to advise partial splenectomy with continued
immunotherapy as the success of immunotherapy was inherent
with spleen preservation.
The RF-based splenic resection was performed at the end of
December.2.2. Surgical technique
Following informed consent, the patient was placed in the left
lateral position under general anesthesia, and a left subcostal
incision was made. There were no other pathological lesions
noted. The dissection was performed along the avascular
peritoneal attachments such as splenocolic and lienorenal
Figure 3. Sequential application of the RF probe (Habib 4X) to create parallel
ablation lines 1cm adjacent to tumor.
Figure 5. Resection at proximal margin of 12 to 14mm width necrotic splenic
parenchyma adjacent to tumor (Note: 10mm of extra-safety margin at the
resection margin).
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ligated in the gastrosplenic ligament. The spleen was gently
grasped and displaced medially toward the incision area, and the
site and size of the tumor were conﬁrmed with intraoperative
ultrasound (Fig. 2). The resection margin was marked with argon
diathermy. The aim was to use the 4-needle RF probe to ablate a
plane of resection to achieve a 2cm resection margin away from
the tumor. In this technique, parallel lines of ablation were
created by the sequential application of RF-based device, Habib
4X (AngioDynamics, Inc., New York, NJ) by using the a RF
generator at 60W for optimal splenic parenchymal coagulation.
The ﬁrst ablation line was performed 1cm from the tumor, and
then a second parallel line made between the ﬁrst line and the
tumor edge (Fig. 3). Several transverse applications were required
to create a third line which connected the vertical parallel lines
and ensured complete ablation (Fig. 4). The probe was moved
swiftly in a see-saw fashion over 3 to 5mm of its axis. The
movement of the probe helped to avoid any adherence of the
splenic tissue to the needles. The Habib 4X device effectively
created a 1cm thick area of ablated and coagulated tumor-free
margin. The resection was performed with a scalpel dividing theFigure 4. Sequential application of the RF probe to create transverse ablation
lines which connected to the parallel lines of ablation.
3parenchyma close to the ﬁrst coagulated edge next to the tumor,
leaving ∼10mm of coagulated splenic parenchyma (Figs. 5 and
6). At the end of the resection, the device was used to arrest any
residual bleeding at the resection margin. The postoperative
recovery was smooth and the patient was discharged on the sixth
postoperative day with normal platelets and white blood cells.
The histopathology of the resected specimen revealed ametastatic
melanoma 26mm in the maximum diameter. At 10-month
follow-up after the splenic resection, the patient was well and
without tumor recurrences.3. Discussion
Splenic metastasis is part of the advanced multivisceral metastatic
melanoma disease process. An incidental diagnosis of splenic
metastasis has been made on imaging performed for other
reasons or autopsy.[21–23]
There are many case reports present in the literature which
suggest splenectomy as a therapeutic option. However, due to the
recent success and reported improved survival following the
inception of immune checkpoint blockade drugs (anti-CTLA4,Figure 6. Residual in situ spleen postpartial splenectomy.
[4] Márquez-Rodas I, Cerezuela P, Soria A, et al. Immune checkpoint
Mudan et al. Medicine (2017) 96:49 Medicineanti-PD-1, and anti-PD-L1) there is emerging evidence toward the
role of splenic preservation. The PD-1 receptor is an inhibitory
receptor found on activated T cells.[24–26] The ability of the
activated T cell to produce an effective immune response is
downregulated when PD-1 binds to its ligand (PD-L1) present on
tumor cells. The introduction of antibodies directed against PD-1
(nivolumab, pembrolizumab) or the PD-1 ligand may reinstate an
antitumor immune response by T cells to suppress the melanoma
cells.[27,28]Hence, the effectiveness of these drugs is dependent onT
cell populations together with the fact that the spleen plays an
important and distinctive role in T cell activation. Thus, any
modality which offers spleen preservation would be a more
beneﬁcial proposition. Splenic preservation would assist in
maintaining the physiological functionality of T cells and as a
consequencekeep theoptimal efﬁcacyof checkpoint inhibitors.[29–
35] Our patient in this index report developed pneumonitis, an
uncommon complication encountered with an antiprogrammed
cell death receptor 1 (PD-1)or anti-programmed cell death ligand1
(PD-L1) monoclonal antibody. However, drug-induced pneumo-
nitis is a diagnosis of exclusion, and alternative diagnoses,
including infection and malignancy, need to be sought ﬁrst.[36,37]
There have been no prospective clinical trials done so far to outline
the management of pneumonitis. However, observational studies
suggested an empirical approach in terms of withholding or
stopping the drug with corticosteroid treatment in cases of severe
disease.[38,39]
The present case highlights the importance of spleen preservation
in order to maintain and boost the therapeutic efﬁcacy of
immunotherapy, such as PD-1 inhibitors. To the best of our
knowledge, this is the ﬁrst case report where RF-based partial
splenectomy has been used as an adjunct to PD-1 inhibitors to
control the metastatic melanoma disease process, although this
requires further investigation through the randomized clinical trials.4. Conclusion
The isolated splenic metastasis is a rare phenomenon noted in an
advanced stage of the melanoma. The RF-based spleen-
preserving resection for isolated, solitary splenic metastasis of
melanoma is a feasible approach as it not only preserves the
ongoing efﬁcacy of checkpoint inhibitors by preserving the
physiological T cell milieu, but combined with the immunomo-
dulation properties of RF can produces potentially additional
therapeutic beneﬁt.Acknowledgment
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